Lysophospholipid receptors, as novel conditional danger receptors and homeostatic receptors modulate inflammation—novel paradigm and therapeutic potential

X Wang, YF Li, G Nanayakkara, Y Shao… - Journal of …, 2016 - Springer
X Wang, YF Li, G Nanayakkara, Y Shao, B Liang, L Cole, WY Yang, X Li, R Cueto, J Yu
Journal of cardiovascular translational research, 2016Springer
There are limitations in the current classification of danger-associated molecular patterns
(DAMP) receptors. To overcome these limitations, we propose a new paradigm by using
endogenous metabolites lysophospholipids (LPLs) as a prototype. By utilizing a data mining
method we pioneered, we made the following findings:(1) endogenous metabolites such as
LPLs at basal level have physiological functions;(2) under sterile inflammation, expression
of some LPLs is elevated. These LPLs act as conditional DAMPs or anti-inflammatory …
Abstract
There are limitations in the current classification of danger-associated molecular patterns (DAMP) receptors. To overcome these limitations, we propose a new paradigm by using endogenous metabolites lysophospholipids (LPLs) as a prototype. By utilizing a data mining method we pioneered, we made the following findings: (1) endogenous metabolites such as LPLs at basal level have physiological functions; (2) under sterile inflammation, expression of some LPLs is elevated. These LPLs act as conditional DAMPs or anti-inflammatory homeostasis-associated molecular pattern molecules (HAMPs) for regulating the progression of inflammation or inhibition of inflammation, respectively; (3) receptors for conditional DAMPs and HAMPs are differentially expressed in human and mouse tissues; and (4) complex signaling mechanism exists between pro-inflammatory mediators and classical DAMPs that regulate the expression of conditional DAMPs and HAMPs. This novel insight will facilitate identification of novel conditional DAMPs and HAMPs, thus promote development of new therapeutic targets to treat inflammatory disorders.
Springer